Vincent Chung, MD

Articles by Vincent Chung, MD

ASCO 2025: Insights on NALIRIFOX Use in Metastatic Pancreatic Ductal Adenocarcinoma From the NAPOLI-3 Trial

ByVincent Chung, MD,Alana Hippensteele, Lead Editor

June 5th 2025

Vincent Chung, MD, discusses key findings from the NAPOLI-3 trial and offers guidance for pharmacists on managing toxicities, adjusting dosing, and supporting patients receiving NALIRIFOX for metastatic pancreatic ductal adenocarcinoma.

Latest Updated Articles

Trending on Pharmacy Times

Pharmacists Key to Counseling and Monitoring Patients Transitioning to Low-Sodium Oxybate

Ban Synthetic 7-OH: Natural Leaf Kratom Presents No Major Health Risk

Home

About Us

News